Trump finally issues controversial drug price executive order

It calls for Medicare to test the same price for some expensive prescription drugs that other developed countries do, “the price of the most favored nation.” Other countries typically pay very little for drugs, in large part because their governments often determine the cost – which runs counter to Republicans’ loyalty to the free market system.

Although Trump has slammed the socialist health care systems present in other countries and attacked his Democratic rivals seeking to implement such a setup here, he celebrated linking US prices to the lower costs of peer countries.

“Lower Drugs Primers Just to Sign a New Executive Order! My Most Favored Nation Order will ensure that our country gets the same low price that Big Pharma gives to other countries,” Tweeted Sunday. “The days of global freeriding at the expense of the US are over … and prices are coming down sharply! Also, all discounts for middlemen have ended, further reducing prices.”

The drug, which has been fiercely opposed by the pharmaceutical industry, remains somewhat of a mystery since the President’s original order was signed on July 24. At the time, he said that he is meeting with officials of the pharmaceutical company to present their ideas to be narrowed down. There will be a cost and a moratorium on implementing the action for a month.

However, the meeting never took place, and the White House has been mummified since Trump’s deadline to implement the order passed in late August. The newly issued order extends the scope of the policy to some Part D drugs sold in pharmacies, in addition to some Part B drugs administered in hospitals and doctors’ offices.

On Sunday, White House Deputy Press Secretary Jude Deere said the administration gave drug makers a month to come up with a counter proposal.

“The negotiations did not produce an acceptable alternative, so the president is moving forward,” he said.

The main pharmaceutical industry group, PhRMA, called the move “irresponsible and unqualified” and called it “telling foreign governments how the US facilitates treatment and cure for seniors and people battling devastating diseases” . ”

Other actions signed in July have primarily revamped proposals that the administration has ordered in the past, including importing low-cost medicine from other countries and pharmacy benefit managers in Medicare and Medicaid to drug manufacturers And effectively ban from providing billions of dollars to insurers.

With no influence before the election, executive orders come at a time when Trump is trying to fulfill his long-standing campaign promise to reduce drug prices, although very little movement Have been made. Most of the administration’s actions – including attempts to import the drug from Canada – remain in the resolution phase or have been rejected by the courts.

The day before release, House Speaker Nancy Pelosi and Senate Democratic Leader Chuck Schumer are set to set up a “Your Health, Your Vote” virtual bus tour with Protect Our Care, a leftist advocacy founded by Obama administration health officials Is a group. .

However, they have also come at a time when Trump is preparing drug makers to develop vaccines and treatments for Kovid-19 and are bargaining heavily to do so. Trump has come under fire for his response to the tronovirus epidemic, including last week’s revelation by journalist Bob Woodward that the president knew in early February how deadly it was but downplayed the threat.

In its statement, the pharmaceutical industry also said that the focus of the reforms was “protecting the vital work being done to end COVID-19” and “not gambling” on our ability to win the fight against COVID-19 to the nation should do. Ubiquitous epidemic. “

The president first formulated an international pricing index proposal in October 2018 to set Medicare reimbursement levels for certain drugs at other countries in their own cost, seeking to stand on health care days before Republicans’ mid-election having had. It called for a “target price” to be paid 126% of the average for other countries.

The concept, supported by Democratic Vermont Sen. Bernie Sanders, has always failed in the past after drug companies ran into major resistance.

Jason Hoffman of CNN contributed to this story.